These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18097577)

  • 41. Gefitinib is effective against juvenile pilocytic astrocytoma in vitro.
    Foreman NK; Gore L; Wells D; Straessle J; Heideman R; Donson AM
    Pediatr Blood Cancer; 2006 Sep; 47(3):293-8. PubMed ID: 16206208
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
    Cohen EE; Lingen MW; Martin LE; Harris PL; Brannigan BW; Haserlat SM; Okimoto RA; Sgroi DC; Dahiya S; Muir B; Clark JR; Rocco JW; Vokes EE; Haber DA; Bell DW
    Clin Cancer Res; 2005 Nov; 11(22):8105-8. PubMed ID: 16299242
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib.
    Hickinson DM; Marshall GB; Beran GJ; Varella-Garcia M; Mills EA; South MC; Cassidy AM; Acheson KL; McWalter G; McCormack RM; Bunn PA; French T; Graham A; Holloway BR; Hirsch FR; Speake G
    Clin Transl Sci; 2009 Jun; 2(3):183-92. PubMed ID: 20443891
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Niwa H; Wentzel AL; Li M; Gooding WE; Lui VW; Grandis JR
    Clin Cancer Res; 2003 Oct; 9(13):5028-35. PubMed ID: 14581378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma.
    Tan DSW; Chong FT; Leong HS; Toh SY; Lau DP; Kwang XL; Zhang X; Sundaram GM; Tan GS; Chang MM; Chua BT; Lim WT; Tan EH; Ang MK; Lim TKH; Sampath P; Chowbay B; Skanderup AJ; DasGupta R; Iyer NG
    Nat Med; 2017 Oct; 23(10):1167-1175. PubMed ID: 28920960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression.
    Lin HQ; Katsifis A; Meriaty H
    Anticancer Res; 2010 Dec; 30(12):4899-905. PubMed ID: 21187468
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gefitinib inhibits sodium phosphate co-transporter III isoform 1 in a model of human malignant glioma.
    Puech C; Prevot N; Perek N
    Anticancer Res; 2014 Nov; 34(11):6527-35. PubMed ID: 25368255
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.
    Young NR; Soneru C; Liu J; Grushko TA; Hardeman A; Olopade OI; Baum A; Solca F; Cohen EE
    Target Oncol; 2015 Dec; 10(4):501-8. PubMed ID: 25559287
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC).
    Nagalakshmi K; Jamil K; Pingali U; Reddy MV; Attili SS
    Biomarkers; 2014 May; 19(3):198-206. PubMed ID: 24712396
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma.
    Su MC; Lien HC; Jeng YM
    Cancer Lett; 2005 Jun; 224(1):117-21. PubMed ID: 15911107
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells.
    Sebastian S; Azzariti A; Accardi R; Conti D; Pilato B; LaCalamita R; Porcelli L; Simone GM; Tommasi S; Tommasino M; Paradiso A
    Int J Mol Med; 2008 Jun; 21(6):809-17. PubMed ID: 18506376
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment.
    La Fleur L; Johansson AC; Roberg K
    PLoS One; 2012; 7(9):e44071. PubMed ID: 23049743
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gefitinib-related gene signature in bladder cancer cells identified by a cDNA microarray.
    Inoue R; Matsuyama H; Yano S; Yamamoto Y; Iizuka N; Naito K
    Anticancer Res; 2006; 26(6B):4195-202. PubMed ID: 17201133
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
    Hah JH; Zhao M; Pickering CR; Frederick MJ; Andrews GA; Jasser SA; Fooshee DR; Milas ZL; Galer C; Sano D; William WN; Kim E; Heymach J; Byers LA; Papadimitrakopoulou V; Myers JN
    Head Neck; 2014 Nov; 36(11):1547-54. PubMed ID: 24123531
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.
    Ozawa S; Kato Y; Ito S; Komori R; Shiiki N; Tsukinoki K; Ozono S; Maehata Y; Taguchi T; Imagawa-Ishiguro Y; Tsukuda M; Kubota E; Hata R
    Cancer Sci; 2009 Nov; 100(11):2202-9. PubMed ID: 19673887
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.
    Lee JW; Soung YH; Kim SY; Nam HK; Park WS; Nam SW; Kim MS; Sun DI; Lee YS; Jang JJ; Lee JY; Yoo NJ; Lee SH
    Clin Cancer Res; 2005 Apr; 11(8):2879-82. PubMed ID: 15837736
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro.
    Erjala K; Zhang N; Sundvall M; Kulmala J; Elenius K; Grénman R
    Radiother Oncol; 2007 Oct; 85(1):138-45. PubMed ID: 17923163
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Heterozygous mutation (G/G→G/A) at nt 2607 of the EGFR gene is closely associated with increases in EGFR copy number and mRNA half life, but impaired EGFR protein synthesis in squamous cell carcinomas of the head and neck - implication for gefitinib efficacy.
    Nakazaki K; Kato Y; Taguchi T; Inayama Y; Ishiguro Y; Kondo N; Horiuchi C; Sakakibara A; Tsukuda M
    Oncol Lett; 2010 Nov; 1(6):1017-1020. PubMed ID: 22870104
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Studies on the inhibition of feline EGFR in squamous cell carcinoma: enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors.
    Bergkvist GT; Argyle DJ; Pang LY; Muirhead R; Yool DA
    Cancer Biol Ther; 2011 Jun; 11(11):927-37. PubMed ID: 21464610
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR.
    Wang D; Su L; Huang D; Zhang H; Shin DM; Chen ZG
    Mol Cancer; 2011 Sep; 10():116. PubMed ID: 21939503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.